The company offers minimally invasive medical devices and methods for treating obesity, metabolic syndrome, and type 2 diabetes mellitus by optimizing fat distribution and metabolism. They specialize in the liposuction and body sculpting market, bariatric market, and fat autograft and adipocyte-derived stem cell processing markets. Their Obesity Control Division is developing devices and methods for endoscopic visceral lipectomy, which has the potential to help the 1.3 billion obese people worldwide by offering a safer and more effective alternative to current surgical bariatric treatments.